Live genomic analysis active

Decode disease
before it begins.

Helix combines next-generation sequencing with proprietary AI to deliver precision medicine insights at population scale. We turn 3.2 billion base pairs into actionable clinical intelligence.

Genomic Analysis — Patient 7841-B
Processing
Pathogenic Variants
78%
Coverage Depth
92%
Drug Response Score
64%
Confidence Index
87%
BRCA1 c.68_69del
Breast Cancer Risk
High Risk
CYP2C19*2
Drug Metabolism
Intermediate
APOE ε4/ε4
Alzheimer's Risk
Moderate
FTO rs9939609
Metabolic Marker
Low Risk
14M+
Genomes sequenced
99.98%
Base call accuracy
47
FDA-cleared assays
6h
Avg. report turnaround
Step 01 — Sequence

From blood draw to base pairs in hours

Our CLIA-certified laboratory processes samples using Illumina NovaSeq X Plus, achieving 30x whole genome coverage with industry-leading turnaround times.

  • Whole genome sequencing — 3.2 billion base pairs
  • RNA sequencing for gene expression analysis
  • Methylation profiling for epigenetic insights
  • Structural variant detection at single-nucleotide resolution
Step 02 — Analyze

AI that thinks like a geneticist

Our proprietary Helix Neural Engine is trained on 14 million sequenced genomes and 40 years of clinical outcomes data. It detects patterns invisible to human review.

  • Variant classification across 8 pathogenicity tiers
  • Drug-gene interaction prediction for 3,200+ medications
  • Polygenic risk scoring for 50+ complex traits
  • Rare disease differential with 98.7% sensitivity
Step 03 — Act

Clinical reports that drive decisions

Helix reports integrate directly into Epic and Cerner workflows, surfacing genetic insights at the point of care — when they matter most.

  • EHR-integrated variant alerts and clinical flags
  • Pharmacogenomic dosing recommendations
  • Cascade testing guidance for at-risk family members
  • Patient-facing summary reports in 14 languages

Building the future of medicine

Phase III — Oncology
Pan-Cancer Early Detection
ctDNA liquid biopsy assay detecting 50+ cancer types from a single blood draw with 94.2% sensitivity.
Phase III2026 FDA submission
Phase II — Neurology
Alzheimer's Risk Stratification
Polygenic risk + CSF biomarker integration for presymptomatic AD identification in at-risk populations.
Phase II1,240 enrolled
Phase I — Cardiology
HCM Predictive Screening
Sarcomere variant panel with AI risk model for familial hypertrophic cardiomyopathy cascade testing.
Phase IIND granted